ROCKWELL MEDICAL, INC. Net Income (Loss) Available to Common Stockholders, Diluted
ROCKWELL MEDICAL, INC. (RMTI) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$1.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-13
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$1.33M.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$1.60M.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$554.00K.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$1.75M, a 222.50% decline year-over-year.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$5.47M.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$782.00K.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$8.59M.
- ROCKWELL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$18.68M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.33M 10-Q · filed 2026-08-13 | -$2.93M 10-Q · filed 2026-08-13 | -$3.49M derived: sum of 3 quarters · filed 2026-08-13 | -$5.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.60M 10-Q · filed 2026-05-07 | -$2.16M derived: sum of 2 quarters · filed 2026-05-07 | -$3.91M derived: sum of 3 quarters · filed 2026-05-07 | -$5.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$554.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$2.31M derived: sum of 2 quarters · filed 2026-03-26 | -$3.95M derived: sum of 3 quarters · filed 2026-08-13 | -$5.47M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$1.75M 10-Q · filed 2025-11-12 | -$3.40M derived: sum of 2 quarters · filed 2026-08-13 | -$4.91M 10-Q · filed 2025-11-12 | -$5.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.65M 10-Q · filed 2026-08-13 | -$3.16M 10-Q · filed 2026-08-13 | -$4.18M derived: sum of 3 quarters · filed 2026-08-13 | -$2.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.51M 10-Q · filed 2026-05-07 | -$2.53M derived: sum of 2 quarters · filed 2026-05-07 | -$1.10M derived: sum of 3 quarters · filed 2026-05-07 | -$817.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $413.00K derived: sum of 2 quarters · filed 2026-03-26 | $698.00K derived: sum of 3 quarters · filed 2026-03-26 | -$782.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.43M 10-Q · filed 2025-11-12 | $1.72M derived: sum of 2 quarters · filed 2025-11-12 | $236.00K 10-Q · filed 2025-11-12 | -$1.68M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $285.00K 10-Q · filed 2025-08-14 | -$1.39M 10-Q · filed 2025-08-14 | -$3.11M derived: sum of 3 quarters · filed 2025-08-14 | -$4.98M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.73M 10-Q · filed 2025-05-12 | -$3.39M derived: sum of 2 quarters · filed 2025-05-12 | -$5.26M derived: sum of 3 quarters · filed 2025-05-12 | -$8.57M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$3.53M derived: sum of 2 quarters · filed 2025-03-20 | -$6.84M derived: sum of 3 quarters · filed 2025-03-20 | -$8.59M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$1.87M 10-Q · filed 2024-11-12 | -$5.18M derived: sum of 2 quarters · filed 2024-11-12 | -$6.93M 10-Q · filed 2024-11-12 | -$9.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$3.31M 10-Q · filed 2024-08-08 | -$5.05M 10-Q · filed 2024-08-08 | -$7.42M derived: sum of 3 quarters · filed 2024-08-08 | -$11.61M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.75M 10-Q · filed 2024-05-14 | -$4.11M derived: sum of 2 quarters · filed 2024-05-14 | -$8.30M derived: sum of 3 quarters · filed 2024-05-14 | -$13.27M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$6.55M derived: sum of 2 quarters · filed 2024-03-21 | -$11.52M derived: sum of 3 quarters · filed 2024-03-21 | -$18.68M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$4.19M 10-Q · filed 2023-11-14 | -$9.16M derived: sum of 2 quarters · filed 2023-11-14 | -$16.32M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$4.97M 10-Q · filed 2023-08-14 | -$12.13M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$7.16M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |